Trial Profile
To compare re-hospitalisation rates in hospitalised patients with bipolar disorder recieving Aripiprazole, Fluphenazine, Haloperidol,Paliperidone or Risperidone
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 May 2017
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary) ; Fluphenazine; Haloperidol; Paliperidone; Risperidone
- Indications Bipolar disorders
- Focus Therapeutic Use
- 24 May 2017 Results presented at the 22nd Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research
- 24 May 2017 New trial record